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Abstract
Background: Methotrexate (MTX) is one of the most widely used medications to treat rheumatoid arthritis (RA),
and recent studies have also suggested the potential benefit of the drug for the treatment of osteoarthritis (OA)
of the knee. MTX is commonly administered in oral formulations, but is often associated with systemic adverse
reactions. In an attempt to address this issue, we have shown previously that a conjugate of hyaluronic acid (HA)
and MTX exhibits potential as a drug candidate for intra-articular treatment of inflammatory arthritis. In this study,
we compare the efficacy and safety of an optimized HA-MTX conjugate, DK226, with that of MTX in inflammatory
arthritis rat models.
Methods: In vitro activity of DK226 was assessed in human fibroblast-like synoviocytes (HFLS) and a synovial sarcoma
cell line, SW982. Release of MTX from DK226 was investigated after incubation with rabbit synovial tissue homogenate
or synovial fluid. In vivo efficacy of DK226 was evaluated in antigen-induced arthritis (AIA) and collagen-induced arthritis
(CIA) in the rat knee. Pharmacokinetics and hematological toxicity after treatment with oral MTX or an intra-articular
injection of DK226 were compared in AIA.
Results: Proliferation of HFLS and SW982 cells was inhibited by DK226, and the inhibitory activity was reversed by
cotreatment with excess HA or anti-CD44 antibody. MTX was released from DK226 by incubation with rabbit synovial
tissue homogenate or synovial fluid at pH 4.0, but not at pH 7.4. AIA was ameliorated by intra-articular DK226, but
not by HA, as potently as oral MTX. Hematological toxicity was induced by oral MTX, but not by DK226. The maximum
plasma concentration of MTX after oral MTX was 40 times higher than the concentration of MTX after an intra-articular
injection of DK226. Knee swelling in AIA was inhibited by intra-articular injections of DK226, but not by free MTX or
a mixture of HA and MTX. In CIA, an injection of DK226 into the right knee joint significantly reduced swelling and
synovial inflammation of the treated knee joint, but had no effect on the untreated contralateral knee joint.
Conclusions: DK226 exerted anti-arthritic effects in two different models of arthritis. The conjugate had a wider
therapeutic window than oral MTX, and could be a future drug for treatment of arthritic disorders, including
inflammatory OA.
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Background
Rheumatoid arthritis (RA) and osteoarthritis (OA) are
the most common chronic inflammatory joint diseases,
but despite decades of extended research, there are still
unmet needs in the treatment of these arthritic dis-
orders, and notably, there are no disease-modifying OA
drugs available at present [1]. However, recent evidence
indicates that synovial inflammation is also implicated in
many of the signs and symptoms of OA, including pain,
joint swelling, and effusion. Synovial inflammation in
OA resembles that in RA, but the intensity and nature
of inflammation may differ between OA and RA [2].
Synovial inflammation is, therefore, a potential target for
therapeutic intervention to control joint symptoms, not
only in RA but also in OA [2–8].
Methotrexate (MTX) is one of the most frequently
used disease-modifying anti-rheumatic drugs, and is
considered to act through a mechanism of anti-
inflammation [9–12]. Because recent clinical studies
have shown that MTX also reduces pain and inflamma-
tion in knee OA, MTX has been suggested as a new
therapeutic option for OA treatment [13, 14]. However,
although MTX is widely used as an effective therapeutic
agent in RA, MTX is frequently associated with adverse
events such as pneumonitis, liver fibrosis, and myelosup-
pression, and generally, the main reason for discon-
tinuing MTX is not a lack of efficacy, but its side effects
[15, 16]. Therefore, even if MTX were available to treat
a chronic disease like OA, there would be serious con-
cerns about its safety aspects. Moreover, an oral treat-
ment such as MTX is not appropriate to treat OA,
which is usually regarded as a localized disease, for
which the optimal treatment is a therapy applied directly
to the affected joint [17, 18].
Intra-articular drug delivery can be useful for treating
inflamed joints when a small number of joints are
affected, or for joints that do not respond to systemic
medications [19, 20]. It has the advantage of targeting
drugs to the site of action, thus avoiding systemic side
effects. However, the outcomes have not been satisfac-
tory, because drugs administered as an intra-articular
formulation rapidly disappear from the joint cavity [19].
To date, various intra-articular drug delivery systems for
MTX have been reported [20], including liposomes [21],
microspheres [22, 23], and hydrogels [24]. Although
there have been some promising preclinical results, none
of them have so far been applied in the treatment of
arthritic patients. This may be due to the problems
common to intra-articular drug delivery systems, such as
biocompatibility, tolerability, safety, efficacy, and manu-
facturing technology [19, 25, 26].
Hyaluronic acid (HA), which is a high molecular
weight (MW) polysaccharide composed of repeating
subunits of N-acetyl glucosamine and glucuronic acid, is
responsible for the viscoelastic properties of synovial
fluid, but in OA patients the MW and concentration of
HA is decreased [27–30]. In current treatment, intra-
articular HA is widely used as viscosupplementation or a
symptom-modifying treatment for OA of the knee,
because it is generally thought that HA preparations
reverse the impaired viscosity and elasticity of synovial
fluid that have been caused by the pathologic condition
of affected joints and thereby eliminate pain [28–32]. In
addition, HA properties — biodegradability, biocompati-
bility, ease of chemical modification, sufficient safety for
long-term clinical use in humans, and an established
manufacturing technique — are uniquely suited to ad-
dress the problems with intra-articular drug delivery
mentioned above [33–36].
We have therefore been investigating the use of HA as a
carrier that will increase the residence time of MTX in af-
fected joints. We believe that HA–MTX conjugates would
be a rational combination of these two clinically validated
agents, since in such conjugates they each retain their
respective biological activity. We reported previously that
once-daily intra-articular injections of prototype HA–MTX
conjugates showed anti-inflammatory effects in an antigen-
induced arthritis model (AIA) [37]. We then optimized the
peptide, the linker, the MW, and the binding ratio of MTX
to obtain a clinical candidate, DK226 [38] (Fig. 1).
In the present study, we further evaluated DK226 for its
mechanisms of action, pharmacokinetics (PK) properties,
and preliminary safety and efficacy in two different rat
models of arthritis, AIA and collagen-induced arthritis (CIA).
Since there are no animal models with a proven track record
of modeling the OA synovitis seen in human disease, we
used these two inflammatory rat arthritis models to evaluate
the potential use of DK226 in the treatment of inflammatory
OA. Results obtained in this study suggest the possible use
of DK226 as a safe and efficacious agent in arthritic diseases.
Methods
Animals
Ten-week-old female DA/Slc rats were obtained from
Japan SLC (Shizuoka, Japan). Eleven-week-old male Kbl:JW
rabbits were purchased from Oriental Yeast Co., Ltd.
(Tokyo, Japan). Five-week-old male LEW/Crj rats were ob-
tained from Charles River Laboratories Japan (Yokohama,
Japan). All animal experiments were ethically performed in
accordance with the Guidelines for the Care and Use of
Laboratory Animals at Chugai Pharmaceutical Co. Ltd,
which is accredited by the Association for Assessment and
Accreditation of Laboratory Animal Care (AAALAC).
Preparation of DK226 and MTX-α peptides
DK226 (Fig. 1), MTX-α-phenylalanine (MTX-α-Phe) and
MTX-α-phenylalanine-phenylalanine (MTX-α-Phe-Phe)
were prepared as described previously [38]. Preparations
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of DK226 with MW of >1900 kDa and with MTX bind-
ing ratio (the percentage of the HA carboxylic acid
groups that are replaced by MTX) ranging from 1.9 to
3.8 % were used for the following experiments.
Cell proliferation assay
Human fibroblast-like synoviocytes (HFLS) (Cell Appli-
cants, Inc., San Diego, CA, USA) or human synovial
sarcoma cell line SW982 (ATCC, Manassas, VA, USA)
were seeded at 5000 cells/well and cultured in Iscove’s
modified Dulbecco’s medium containing 5 % fetal bovine
serum and 1× Antibiotic-Antimycotic (Gibco, Life Tech-
nologies, Tokyo, Japan) to allow the cells to adhere to the
plates. HFLS were stimulated by 10 ng/mL of recombinant
human tumor necrosis factor alpha (TNF-α) (R&D
Systems, Minneapolis, MN, USA ) and incubated with HA
(Suvenyl®, approximately 1900 kDa, Chugai Pharmaceutical
Co., Ltd., Tokyo, Japan) or DK226 at 37 °C. SW982 cells were
incubated with DK226 or MTX in the presence or absence
of 1 μg/mL of anti-CD44 antibody (BU75) (Ancell
Corporation, Stillwater, MN, USA) or control IgG2a (RPC
5; Ancell) at 37 °C. After 72-h incubation, 3H-deoxyuri-
dine (Moravek Biochemicals, Inc., Brea, CA, USA) was
added into the media, and the mixture was cultured for
another 48 h (for HFLS) or 4 h (for SW982), followed by
radioassay. Radioactivity was calculated as a relative value
(% of control), using, as the control, radioactivity in the
group of cells cultured without any added test substance.
MTX release after incubation with rabbit synovial tissue
homogenates or synovial fluid
Twelve-week-old male rabbits were subjected to a partial
meniscectomy, as described previously [39]. Synovial fluids
were collected from the knee joints of the rabbits at 8, 11,
15, 18, 25, and 29 days after the operation and then com-
bined and stored at −80 °C until use. Twenty-nine days after
the operation, the animals were euthanized by exsanguin-
ation under ether anesthesia, and the synovial tissues were
dissected, weighed, and homogenized in a 4-fold volume
of 0.05 mol/L Tris (hydroxymethyl) aminomethane–
hydrochloride (Tris–HCl) buffer (pH 8.0) containing
0.138 mol/L sodium chloride (NaCl) and 0.0027 mol/L po-
tassium chloride (KCl). The homogenates were combined
and stored at −80 °C until use. The protein contents of the
combined synovial tissue homogenates and the combined
synovial fluids were determined by Bradford protein assay.
Next, 40 μg/mL of DK226 or 10 μg/mL of MTX-α-Phe
(reference compound to measure metabolic activity) was
incubated with or without synovial tissue homogenate or
synovial fluids (500 μg protein/mL) in 0.1 mol/L acetate buf-
fer (pH 4.0) or 0.1 mol/L phosphate buffer (pH 7.4) at 37 °C
for 3, 8, and 24 h. At the end of each incubation period,
100 μL of the reaction mixture was collected and mixed
with 1 mL of ethanol. After evaporation of the solvent
under nitrogen, the residues were dissolved in 100 μL of
10 mmol/L ammonium acetate in 10 % acetonitrile.
Concentrations of MTX, MTX-α-Phe, and MTX-α-
Phe-Phe were measured by liquid chromatography/
quadrupole time-of-flight mass spectrometry (Q-TOF Ul-
tima API; Waters, Milford, MA, USA). To assess the meta-
bolic stability of MTX-α-Phe, the percent peak area of intact
MTX-α-Phe and MTX released from MTX-α-Phe were
monitored by liquid chromatography with UV detection
(LC-UV) at 215 nm (Magic 2002; AMR Inc., Tokyo, Japan).
Induction and treatment of AIA
Six-week-old male LEW/Crj rats were immunized as
previously described [38]. On the day of arthritis
induction (day 0), rats were treated with a single intra-
articular injection of 50 μL of modified bovine serum
albumin (mBSA) (Merck, Darmstadt, Germany) aqueous
solution (2 mg/mL) into the right knee joint. The left
knee joint was untreated and served as the control.
MTX, at a dose of 1.25 mg/kg was administered orally five
times a week from 7 days before inducing arthritis (day −7).
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Fig. 1 Chemical structure of DK226 [37]. DK226 consists of four parts: MTX, peptide, linker, and HA. MTX binds through its α-carboxylic acid.
Peptide and linker are α–Phe–Phe and –NH–(CH2)2–NH–, respectively
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intra-articularly administered into the right knee joint in
an amount of 50 μL (0.5 mg HA-equiv, 30 nmol MTX-
equiv) on day −7, day −1, day 7, and day 14. In a separate
experiment, HA (0.5 mg), free MTX (25 nmol), a mixture
of HA (0.5 mg) and MTX (25 nmol), or DK226 (0.5 mg
HA-equiv, 25 nmol MTX-equiv) was intra-articularly
administered into the right knee joint on day–7, day −1,
and day 7. Knee joint swelling was assessed as previously
described [38].
Assessment of hematological toxicity in AIA
Blood samples were collected from the tarsal veins of
AIA rats at 24 h after treatment with oral MTX or
DK226 on day14, and were assayed for hematological
analysis. White blood cells, red blood cells, hemoglobin,
hematocrit, and platelet values were measured with an
automatic cell counter (F-820) (Sysmex, Kobe, Japan).
Measurements of plasma MTX in AIA
Serial blood samples were collected from AIA rats on day
14 at 0 h (immediately before treatment) and at 0.25, 0.5, 1,
2, 4, 8, and 24 h after treatment with oral MTX, and at 4, 8,
24, 48, and 72 h after treatment with DK226. Plasma MTX,
MTX-α-Phe, and MTX-α-Phe-Phe levels were measured by
liquid chromatography-tandem mass spectrometry (LC-
MS/MS). Briefly, 20 μL of 12.5 ng/mL of internal standard
and 1 mL of 1 % (v/v) formic acid in acetonitrile was added
to 100 μL of rat plasma and stirred for 2 min. After centrifu-
gation (1710 × g, 5 min, 4 °C), the supernatant was collected
and dried under nitrogen. The residues were dissolved in
60 μL of 4 % (w/v) trichloroacetic acid, and the supernatant
was analyzed by LC-MS/MS (API 4000, AB SCIEX,
Framingham, MA, USA). Lower limits of quantification
(LLOQ) were 50 pg/mL for MTX and 100 pg/mL for
MTX-α-Phe and MTX-α-Phe-Phe. PK parameters [time to
reach maximum plasma concentration (Tmax), maximum
plasma concentration (Cmax), area under the plasma
concentration-time curve calculated from time zero to infin-
ity (AUCinf), and terminal phase elimination half-life (t1/2)]
were calculated by a non-compartmental model.
Induction and treatment of CIA
Eleven-week-old female DA/Slc rats were immunized
intradermally at four sites on the back with 0.3 mg of
bovine type II collagen (Collagen Research Center,
Tokyo, Japan) emulsified with an equal volume of
incomplete Freund’s adjuvant (Difco, Detroit, MI, USA)
on day 0. Vehicle (saline), HA (0.5 mg), or DK226
(0.5 mg HA-equiv, 26 nmol MTX-equiv) was adminis-
tered into the right knee joint in an amount of 50 μL at
5-day intervals from day 0 to day 20. The left knee joint
was untreated. Three animals were not immunized and
served as the control (Normal). Knee joint swelling was
assessed by measuring the width of each knee joint with
calipers on days 0, 5, 10, 13, 15, 17, 20, and 23. On day
23, animals were euthanized by exsanguination under
anesthesia, and the right knee joints were harvested for
histological evaluation.
Histological evaluation
The right knee joints of the CIA rats were fixed over-
night in 20 % neutral-buffered formalin at room
temperature. The samples were dehydrated and embed-
ded in paraffin, and then cut on the midsagittal plane to
examine the synovium and cut on the longitudinal plane
to examine the lateral femoral condyle. Sections (3 μm
thick) were stained with hematoxylin and eosin or safra-
nin O/fast green and evaluated according to the follow-
ing semiquantitative grading scale: 0 = no pathological
changes; 1 =minimal (minimal changes, or lesions in-
volving <25 % of the whole section); 2 = slight (obvious
changes, or lesions affecting 25–50 % of the whole
section); 3 =moderate (relatively severe changes, or
lesions involving 50–75 % of the whole section); 4 = severe
(very severe changes, or lesions affecting >75 % of the whole
section). Synovium was examined for exudation in the joint
cavity, fibrosis, granulation tissue formation, proliferation of
synovial cells, inflammatory cell infiltration, and edema. The
lateral femoral condyle was assessed for decrease in safranin
O staining, osteophyte formation, destruction of cartilage,
destruction of cortical bone, and pannus formation.
Statistical analysis
Statistical significances were estimated by unpaired
Student’s t test and Wilcoxon rank sum test using a statis-
tical software package (SAS) version 6.12; SAS Institute
Japan, Tokyo, Japan) with the significance level set to 5 %.
Results
Anti-proliferative effects on synovial cells
To verify the biological activity of DK226 and to confirm
whether the conjugate binds to HA receptors, we exam-
ined the effects of DK226 on proliferation of synovial
cells with or without exogenously added HA or anti-
CD44 antibody. TNF-α-induced proliferation of HFLS
cells was inhibited by DK226, but not by HA (up to
1 mg/mL), in a dose-dependent manner (Fig. 2a). However,
the inhibition by DK226 (0.1 mg/mL) was reversed by
adding exogenous HA (1 mg/mL) (Fig. 2b). This implies
the involvement of a HA receptor, such as CD44, in the
anti-proliferative effects induced by DK226. In preliminary
experiments, the inhibitory effect of DK226 was rescued by
adding anti-CD44 antibody, but anti-CD44 antibody itself
stimulated TNF-α-induced proliferation of HFLS cells. To
address this problem, we used a synovial cell line, SW982,
in which anti-CD44 antibody had no effect on the prolifera-
tion of the cells. Cell proliferation of SW982 was also inhib-
ited by DK226 in a dose-dependent manner; the potency of
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DK226 was comparable to that of free MTX (Fig. 2c). The
inhibitory effect of DK226 (0.1 and 0.01 mg/mL) in SW982
was reversed by adding anti-CD44 antibody, but not by
adding control IgG2a antibody (Fig. 2d).
Release of MTX from DK226
In DK226, MTX binds to the HA backbone via a peptide
(α-Phe-Phe) and an alkyl linker (Fig. 1). We previously
demonstrated that MTX-α peptides were susceptible to
cleavage by cathepsins to release MTX at acidic pH [38].
Since cathepsins are abundantly expressed in synovial tissue
and synovial fluid [40], we expected that MTX would be re-
leased from DK226. To examine this possibility, DK226
was incubated with synovial tissue homogenate or synovial
fluid from the knee of a rabbit OA model [39]. As shown in
Table 1, MTX was released from DK226 in the presence of
synovial tissue or synovial fluid at pH 4.0, but not at
pH 7.4. MTX-α peptides were detected in the culture
media when incubated with synovial fluid at pH 4.0, but
neither MTX nor MTX-α peptides were found when incu-
bated in buffer alone (pH 4.0 or pH 7.4) (data not shown).
The percentage of reference compound (MTX-α-Phe) after
24-h incubation with synovial tissue homogenate and with
synovial fluid was 100 % for both at pH 7.4 (after 3-h incu-
bation), or 0 % and 80.1 % respectively at pH 4.0 (Table 1),
whereas the percentage in buffer alone was 100 % at both
pH 4.0 and pH 7.4 (data not shown).
Efficacy and safety of DK226 in AIA
A significant reduction in knee swelling was observed with
once-weekly intra-articular DK226, but HA had only a
marginal effect on day 7 (Fig. 3a). Efficacy of DK226 was
comparable to that of oral MTX. To compare the safety of
DK226 and oral MTX, we examined the effects of these
two treatments on hematological parameters in AIA rats at
24 h after treatment with oral MTX or DK226 on day 14.
Although oral MTX reduced white blood cells (P < 0.05),
red blood cells (P < 0.05), hemoglobin (P < 0.05), and
hematocrit values, and increased platelets, DK226 did not
show any hematological abnormalities (Fig. 3b). The MTX
plasma profiles after DK226 or oral MTX are shown in
Fig. 3c, and their PK parameters are summarized in Table 2.
The plasma MTX concentration peaked at 72,600 pg/mL
at 0.9 h after oral administration of MTX, and returned to
the control level by 24 h (AUCinf: 365 ng∙h/mL, t1/2:
2.78 h). For animals treated with DK226, the plasma MTX
rose gradually to a level of 1900 pg/mL at 20–24 h after
articular injection, and a low plasma concentration was
maintained up to 72 h (AUCinf: 68.4 ng∙h/mL, t1/2: 11.2 h).
MTX-α-Phe and MTX-α-Phe-Phe concentrations were
below the LLOQ (<100 pg/mL).
a b
c d
Fig. 2 Effect of DK226 on proliferation of human synovial fibroblast-like cells (HFLS) and of human synovial sarcoma cell line SW982. a Inhibition of
tumor necrosis alpha (TNF-α)-induced proliferation of HFLS by hyaluronic acid (HA) or DK226 at increasing, equivalent HA concentrations. b Effect of
exogenously added HA on the anti-proliferative effect of DK226 in HFLS. c Inhibition of proliferation of SW982 by methotrexate (MTX) or DK226 at
increasing, equivalent MTX concentrations. d Effect of exogenously added anti-CD44 antibody (BU75) and anti-IgG2a (control antibody) on
the anti-proliferative effect of DK226 in SW982. Values are means and standard error of the mean (SEM) (n = 4)
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To demonstrate the importance of the conjugation
between HA and MTX in DK226, the effects of weekly
intra-articular injections of DK226, free MTX, free HA,
and a mixture of HA and MTX on AIA were compared.
As shown in Fig. 3d, AIA rats treated with DK226 showed
a significant reduction in knee swelling. In contrast, free
MTX, free HA, or a mixture of HA and MTX had no or
little effect on the joint swelling.
Inhibitory efficacy in CIA
To investigate the effect of DK226 in a different arthritic
model, we examined the efficacy of the conjugate in
CIA, in which significant swellings have been induced in
the right and left knee joints. From day 0 to day 23, rats
injected in the right knee joint with DK226 showed a
significant reduction in swelling in the right knee joint,




































































































































































Fig. 3 Effect of DK226 on antigen-induced arthritis (AIA) in rat knee joints. a Effects of intra-articular hyaluronic acid (HA) (0.5 mg), DK226 (0.5 mg
HA-equiv, 30 nmol MTX-equiv), or oral methotrexate (MTX) (1.25/mg/kg) on knee swelling. b Hematological parameters of AIA treated with intra-articular
DK226 or oral MTX. Blood samples were collected at 24 h after treatment on day 14. c MTX plasma profiles following intra-articular DK226 or oral MTX on
day 14. Inserted figure is a magnified view of the MTX plasma concentration after intra-articular DK226. Plasma concentrations of MTX were measured
with liquid chromatography-tandem mass spectrometry (LC-MS/MS). d Effects on knee swelling of intra-articular injections of HA (0.5 mg), MTX (25 nmol),
mixture of HA (0.5 mg) and MTX (25 nmol), and DK226 (0.5 mg HA-equiv, 25 nmol MTX-equiv). Values are means and standard error of the mean (SEM)
(n = 7 in a and b; n = 4 in c; n = 6–8 in d). *P< 0.01: significantly different from HA group (Student’s t test). #P< 0.05: significantly different from Vehicle
group (Student’s t test)
Table 1 Release of MTX and MTX-α peptides from DK226
Treatment pH Released concentration (ng/mL)
MTX MTX-α-Phe MTX-α-Phe-Phe
% of released MTX % peak area of MTX-α-Phe
after 24-h incubation
Synovial tissue homogenate 4.0 8.82 BLQb BLQc 1.2 0e
7.4 BLQa BLQb BLQc 0 100
Synovial fluid 4.0 1.14 2.02 (1.53)d 1.29 (0.783)d 0.5 80.1
7.4 BLQa BLQa BLQa 0 100
DK226 was incubated in rabbit synovial tissue homogenate or synovial fluid at pH 4.0 or pH 7.4 for 24 h at 37 °C. Release of MTX and MTX-α peptides was measured by
LC/Q-TOF-MS. MTX-α-Phe was used as a reference compound to assess the metabolic stability, and the percent peak area of intact MTX-α-Phe and MTX released from
MTX-α-Phe were monitored by LC-UV
MTX methotrexate, Phe phenylalanine, BLQ below lower limit of quantification




ePercent peak area of MTX-α-Phe after 3-h incubation
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Rats injected with HA did not show any difference in
the right and left knee swellings (Fig. 4a). In a separate
experiment, knee swellings were also suppressed in CIA
on day 15 after DK226 had been administered on day 3
and day 10 (data not shown). Histopathological examin-
ation of the right knee joints showed that edema, inflam-
matory cell infiltration, proliferation of synovial cells,
articular cartilage erosion, and a decrease in safranin O
staining were prevented or ameliorated by DK226
(Fig. 4b). In contrast, vehicle or HA had little or no
effect on these arthritic changes (Fig. 4b). Fibrosis,
granulation tissue formation, inflammatory cell infiltra-
tion, and edema in synovium (Fig. 4c), and decrease in
safranin O staining, osteophyte formation, destruction of
cortical bone, and pannus formation in the lateral
condyle of the femur (Fig. 4d) were significantly reduced
in the DK226-treated group as compared to the HA-
treated group.
Discussion
The present study clearly demonstrated that intra-
articular DK226 showed efficacy comparable to that of
oral MTX while avoiding the systemic risks of MTX.
Rats receiving oral MTX showed hematological toxic-
ities, but none of the animals treated with DK226 exhib-
ited any adverse signs (Fig. 3b). In a preliminary toxicity
study in normal rats, once-a-week injections of DK226
to the right and left knee joints for a month resulted in
no histopathological abnormalities in the injected joints,
and displayed no systemic toxicological abnormalities in
hematological, serum biochemical, and histopathological
examinations (data not shown). Our study also demon-
strates that the total amount of MTX administered can
be dramatically reduced by using DK226 rather than oral
MTX. Although 1.25 mg/kg oral MTX given five times a
week (1875 μg/week) was required to exert sufficient ef-
ficacy in AIA, a once-weekly intra-articular injection of
DK226 (corresponding to around 13.6 μg/week) pro-
vided efficacy equivalent to that of oral MTX in the
same model. This difference appears to be attributable
to the difference in the PK properties of the two agents.
PK analysis demonstrated that the Cmax and the AUCinf
following oral administration of MTX were approxi-
mately 40 times and 5 times those of DK226 (Table 2).
We then examined the effects of intra-articular injec-
tions of DK226, HA, free MTX, and a mixture of HA
and free MTX on AIA. Interestingly, intra-articular in-
jection of DK226 (0.5 mg HA-equiv, 25 nmol MTX-
equiv) produced a significant reduction in knee swelling,
whereas the same amount of HA (0.5 mg), free MTX
(25 nmol), or a mixture of HA (0.5 mg) and MTX
(25 nmol) showed no effect on the model (Fig. 3d). It
has been reported that intra-articular injection of MTX
disappears very rapidly from the knee joints and pro-
duces a rapid increase in serum MTX (18–20). Radiola-
beled HAs injected into the knee joints of normal
rabbits declined far more slowly, with average half-lives
of less than 24 h [41], and measurable radioactivity
within the synovial layer and the articular cartilage was
detected up to at least 48 h after injection [41, 42].
These results, combined with the PK parameters de-
scribed before (Table 2), indicate that intra-articular in-
jection of DK226 is cleared from the joint cavity much
more slowly than that of free MTX. In other words, co-
valent conjugation with HA, but not a simple HA and
MTX mixture, can prolong the residence time of MTX
in the joint cavity.
In DK226, MTX and HA are linked with a peptide
linker (Fig. 1), which is susceptible to cleavage by lyso-
somal enzymes including cathepsins [38]. DK226 showed
anti-proliferative effects on HFLS and SW982 cells, and
these effects were reversed by adding exogenous HA or
anti-CD44 antibody (Fig. 2a–d). We previously demon-
strated that prototype HA–MTX conjugates lacking pep-
tide chains failed to show an inhibitory effect on HFLS
proliferation [37]. The receptors recognizing HA, such as
CD44 and receptor for hyaluronan-mediated motility, are
expressed on the surface layer of a wide range of cells, in-
cluding inflammatory cells, synovial cells, and chondro-
cytes [43–46]. A number of studies have shown that HA
receptors, especially CD44, are responsible for the
receptor-mediated cellular uptake and degradation of HA
[47, 48]. As shown in Table 1, when DK226 is incubated
with rabbit synovial tissue homogenate or synovial fluid,
Table 2 Pharmacokinetics parameters for MTX plasma profiles of antigen-induced arthritis after treatment with oral MTX or DK226
Compound Dose Tmax (h) Cmax (pg/mL) AUCinf (ng · h/mL) t1/2 (h)
MTX 1.25 mg/kg, orala 0.9 ± .0.3 72,600 ± 10,000 365 ± 37 2.78 ± 0.18
DK226 50 μL/body, intra-articularb 20.0 ± 8.0 1900 ± 180 68.4 ± 6.1 11.2 ± 0.4
AIA rats were dosed with oral MTX (five times a week, day −7 to day 14) or intra-articular DK226 (weekly, day −7 to day 14) to produce a comparable suppression
of knee joint swelling. Serial blood samples were collected from AIA rats on day 14 at 0 h (immediately before treatment) and at 0.25, 0.5, 1, 2, 4, 8, and 24 h after
treatment with oral MTX, and at 4, 8, 24, 48, and 72 h after treatment with DK226. Plasma concentrations of MTX were then determined by LC-MS/MS. PK parameters
were calculated by a non-compartmental model
MTX methotrexate, Tmax time to reach maximum plasma concentration, Cmax maximum plasma concentration, AUCinf area under the plasma concentration-time
curve calculated from time zero to infinity, t1/2 terminal phase elimination half-life
aThe dose of MTX administered; 375 μg
bThe dose of MTX injected; 13.6 μg
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release of MTX from DK226 occurs at pH 4.0 but not at
pH 7.4. Although the pH of the synovial fluid from knee
joints of AIA and CIA rat models could not be determined
due to their small volume, the pH of synovial fluid in arth-
ritis is reported to be neutral in RA and OA patients [49]
or slightly acidic in a rabbit OA model (normal: pH 7.32,
OA: pH 6.97) [50]. We therefore speculate that DK226 is
distributed in the synovium and can retain a sufficient
amount of MTX until it is internalized and cleaved by
lysosomal enzymes to release the pharmacologically active
form of MTX. However, we cannot exclude the possibility
that, in vivo, the conjugate is degraded in tissues other
than the synovium and degraded by other enzymes in the
affected joints. Taken together, our results suggest that
DK226 can reduce the side effects caused by current
MTX therapy by lowering systemic exposure, by prolong-
ing retention time in the joint, and possibly by HA recep-
tor–mediated internalization and degradation.
Another unique feature of DK226 is that the HA in
DK226 has a high MW (>1900 kDa) comparable to na-
tive HA in the joint. Thus, the conjugate is expected to
act not only as a carrier of MTX, but also to behave like
native HA. Although the mode of action of HA has not
been fully elucidated, intra-articular injection of HA is
used worldwide as a symptom-modifying treatment for
OA of the knee [28–32], and some HA products are
used in Japan for treating RA of the knee [51]. Reports
have suggested that the beneficial effects of HA in OA
of the knee may depend on its rheological properties
and MW, and that high MW HA tends to remain in the
joint cavities longer than low MW HA [29–32]. Low
MW HA has different and more diverse biological activ-
ities than high MW HA [29, 30]. For these reasons, con-
trol of MW is a prerequisite for the design and synthesis
of DK226 [38]. To the best of our knowledge, DK226 is
the first example of a HA–drug conjugate with a MW
comparable to that of native HA.
OA has long been considered a degenerative disease,
but a number of studies have suggested that pain in the
disease is also caused by synovial inflammation [2–6]. The
differences in synovial inflammation in OA and RA were
largely thought to be quantitative rather than qualitative;
angiogenesis [52], T cell accumulation [53] and synovial




Fig. 4 Effect of DK226 on collagen-induced arthritis (CIA) in rat knee joints. a Effect of intra-articular hyaluronic acid (HA) (0.5 mg) or DK226 (0.5 mg
HA-equiv, 26 nmol MTX-equiv) on knee swelling of the right knee (treated) shown on the left panel, and the effect in the left knee (untreated) shown
on the right panel. b Histopathology of the right knee joints after treatment with intra-articular HA or DK226. Sections were stained with safranin O/fast
green. T tibia, M meniscus, F femur. Scale bars indicate 100 μm. c and d Histologic analysis of synovial tissue (c) and lateral condyle of the femur (d).
Values are means and standard error of the mean (SEM) (n = 3–10 in a, c and d: n = 3, Normal + vehicle; n = 9–10, CIA + vehicle, HA or DKA226).
#P < 0.05: significantly different from Normal + vehicle group (Wilcoxon rank sum test). *P < 0.05: significantly different from HA group (Wilcoxon rank
sum test)
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were higher in RA than in OA. But, qualitative differences
have also been observed in immune cell filtration and
cytokine production between synovial inflammation in
OA and RA. It is also reported that synovial inflammation
in OA is located close to a cartilage lesion, in contrast to
RA, which shows diffuse distribution [55]. A recent ran-
domized, placebo-controlled study of MTX demonstrated
that MTX reduced pain and improved synovitis in patients
with symptomatic knee OA [13]. An open-label study of
MTX also demonstrated its analgesic efficacy in OA of the
knee [14]. These findings may indicate that there is a
common underlying mechanism contributing to synovial
inflammation in RA and OA, and that MTX might be a
therapeutic option in the treatment of certain types of OA
[3, 13, 14]. However, since OA is not a life-threatening
disease, treatments are required to have a lower level of
risk than in RA. Moreover, OA, which limits disability to
weight-bearing joints, is not a systemic disease; therefore,
safe and effective means for reducing the systemic toxicity
of MTX are more appropriate for the treatment of OA. In
addressing the particular needs of OA treatment, the safer
toxicity profiles and local administration route of DK226
provide a new option. In CIA, an injection of DK226 in
the right knee produced a significant reduction in joint
swelling in the DK226-treated knee, but not in the contra-
lateral untreated knee. The fact that the conjugate has no
influence on uninjected joints may also indicate that
DK226 has a favorable profile as a local therapy for
treating inflamed joints resistant to systemic medications
or persistent inflammatory monoarthritis [19].
HA products currently available to treat knee OA gen-
erally reduce pain but do not fully control inflammation.
In the present study, we demonstrated the anti-arthritic
efficacy of DK226 in rat AIA and CIA at a dose that is
equivalent to the clinical dose of conventional HA
products used to treat knee OA. Although HA alone
had little or no effect on synovial inflammation, DK226
reduced inflammation significantly in both models. Be-
cause the mechanisms of action of HA and MTX are
distinct, additive or synergistic effects of the two agents
can be expected with DK226 in clinical use. In fact, the
mechanism of action of HA itself is far from clear.
Recent reports show that, although HA disappears from
synovial fluid within several days, the effect of intra-
articular HA products lasts for over 4 weeks [31], and
the possibility that intra-articularly injected HA eliminates
pain by a mechanism other than by simply improving the
viscoelasticity of synovial fluid (as described above) has
been suggested [30–32, 56]. Further examinations are
needed to show whether a reduced dose of DK226 or a
less frequent treatment regimen is also effective.
Even though MTX is widely used for the treatment of
RA, little is known about its direct effect on cartilage. Stud-
ies into the effects of MTX on chondrocyte function have
failed to show any significant effect on cartilage metabol-
ism in vitro or on cartilage degeneration in normal animals
or in rabbit OA models in vivo [57–59]. Although MTX
may prevent cartilage breakdown to some extent in animal
models or in humans, this is probably due to a reduction
in synovial inflammation rather than to its direct effects on
cartilage, since synovial inflammation in OA is considered
to be secondary to mechanical damage of cartilage [60]. In
preliminary experiments, we sought to examine whether
synovial inflammation could be assessed in a rat model
with OA surgically induced by medial meniscectomy in the
knee. While cartilage degeneration was observed, the
degree of synovial inflammation induced in the model was
too mild to measure reliably (data not shown). A low
degree of synovial inflammation was also reported in a
surgical OA model in mouse [61], and a collagenase-
induced OA model in rabbit [39]. We therefore examined
the effects of DK226 in AIA and CIA to demonstrate that
the anti-inflammatory effect of MTX was preserved after
conjugation with HA, and consequently fulfilled the pri-
mary aim of this study, which was to suggest the potential
of DK226 as an anti-arthritic drug. However, AIA and
CIA, which share some clinical and pathological features
with RA in humans [62, 63], are widely used to explore
disease mechanisms of RA and to predict the clinical effi-
cacy of a candidate RA drug, rather than for OA. To better
evaluate the potential of DK226 as an anti-OA drug, the
efficacy of DK226 should be tested in animal models of
OA that involve synovial inflammation resembling that in
human OA. However, to date there are no animal models
that have the same characteristics as inflammatory OA in
humans, and further studies are warranted to establish
new animal models of OA that are valid not only for
DK226 but for other new drugs for inflammatory OA.
Conclusions
DK226 is a new type of high molecular weight HA product
with anti-inflammatory efficacy. DK226 can exert the
effect of the two conjugated agents, MTX and HA, both of
which have long been used to treat arthritis. This could be
a novel approach for the treatment of patients with
arthritic disorders, including inflammatory OA.
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